By Steven D. Vold, MD
By Melissa (Wen-Jeng) Yao, MD, and Jeffrey S. Schultz, MD
By Christopher A. Girkin, MD
Practical research may lead to the better care of patients with glaucoma.
By Albert S. Khouri, MD, and Tony Realini, MD, MPH
By Jess T. Whitson, MD
By Anurag Shrivastava, MD
Technology can help us to communicate with primary health providers to coordinate care.
By George Shafranov, MD
These steps are imperative to accurate diagnosis and treatment.
By Yara P. Catoira-Boyle, MD
This technology enhances physicians’ ability to diagnose disease and its progression, but clinical acumen is still essential.
By Ian Conner, MD, PhD, and Joel S. Schuman, MD
Recently released preservative-free agents will create a new paradigm for the treatment of glaucoma.
By Lawrence M. Hurvitz, MD
The answer is highly variable and influenced by commercial considerations, the patient, and the physician.
By Nicholas P. Bell, MD
Optimizing patients’ outcomes.
By Henry D. Jampel, MD, MHS
This proven and effective treatment modality is a powerful option for initial IOP lowering in the newly diagnosed glaucomatous or ocular hypertensive patient.
By Ahmad A. Aref, MD
The procedure is still viable.
By Richard A. Lehrer, MD
Technical pearls and advice on selecting a device for tube shunt surgery.
By Boris Dilman, MD, and Anjali S. Hawkins, MD, PhD
Stratifying the disease may improve communication between physicians and their patients and educate payors.
By Ronald L. Fellman, MD
By Nathan M. Radcliffe, MD
Dr. Singh predicts how microinvasive glaucoma surgery will affect ophthalmologists’ treatment of the disease and describes one of his star-studded evenings.
Cosopt PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution; Merck and Co., Inc.), a preservative-free formulation of Cosopt, is now available, according to a letter sent to the company’s customers. Approved by ... more >
HarPas International introduced EyeDrops, a smartphone application that reminds patients when and how to administer their eye drops. “The EyeDrops app should enhance medication compliance and adherence in any chronic eye c... more >
The iStent Trabecular Micro-Bypass (Glaukos Corporation) has received approval from the FDA, a decision that has the potential to change the way glaucoma is treated in the United States. The iStent, which is the first ab inter... more >
Advertisement
By Jess T. Whitson, MD
Recently released preservative-free agents will create a new paradigm for the treatment of glaucoma.
By Lawrence M. Hurvitz, MD
Technical pearls and advice on selecting a device for tube shunt surgery.
By Boris Dilman, MD, and Anjali S. Hawkins, MD, PhD
The procedure is still viable.
By Richard A. Lehrer, MD